SwingTrade Member Forum

[RIGATONI]

EVSC could be a nice play here folks....


MONTGOMERY, Texas--(BUSINESS WIRE)--Feb. 13,
2004--Endovasc Inc. (OTCBB: EVSC, news), a drug
development company that pioneers new cardiovascular
and metabolic drug therapies, announced today an
update on the Company's civil lawsuit against J.P.
Turner & Co. LLC et al Inc., Number 02-CV-7313, in the
United States District Court, Southern District of New
York. The complaint is for damages as a result of an
alleged fraud and stock manipulation. The Company is
seeking monetary damages in excess of $200,000,000.



According to Dwight Cantrell, CFO of Endovasc, "Our
attorneys report the present suit against J.P. Turner
& Co., LLC; CCM Group, LLC; LH Financial Services
Corp.; Laurus Master Fund, Ltd.; Laurus Capital
Management, LLC; Keshet Fund, L.P.; Keshet, L.P.,
Keshet Management, Inc.; Talbiya B. Investment Ltd.;
Nesher, Ltd.; Alon Enterprises Ltd.; Balmore Fund
S.A.; Libra Finance S.A.; Celeste Trust Reg.; Patrick
Power; Arie Rabinowitz; Abraham Grin; David Grin;
Eugene Grin; John Clarke; Thomas Hackl; Francois
Morax; Gisela Kindle; Matityahu Kaniel; Seymour Braun;
and Shmuel Lmakias is pending outcome of decisions on
motions now before Judge Preska. Discovery in the case
is stayed pending outcome. Further, our attorneys
report the scope of the scheme is more widespread than
originally contemplated. They anticipate filing
actions on our behalf against other defendants who
participated in the scheme resulting in damages to
us."

According to Endovasc's attorney, James W. "Wes"
Christian, "The theory of our case has been adopted by
other companies that have experienced similar losses
from 'death spiral' conduct by lender/investors. This
spread of other cases and criminal investigations by
the attorneys general or U.S. Attorneys of several
states has been fueled by the civil enforcement
actions and criminal complaint against Thomas Badian,
his brother Andreas, and various SEC actions. Mr.
Thomas Badien is currently believed to be a fugitive.
The conduct of those defendants is the same type of
conduct we believe our defendants have engaged in."

Attorney's John O'Quinn and James W. "Wes" Christian
represent several other bulletin board companies in
their claims for damages against alleged stock
manipulators. The cases claim alleged SEC 10b-5
violations, stock manipulation and fraudulent
misrepresentation by alleged "investors" whose true
intent allegedly was to drive down the company's stock
prices through short-selling in order to receive much
greater amounts of the company's shares when
converting from preferred stock, debenture, or other
convertible provision in financing deals with targeted
bulletin board companies.

About Endovasc

Endovasc, Inc., established in 1996, is an innovative
drug development company with two new cardiovascular
and metabolic drug therapies. Endovasc's mission is to
design the delivery, and release drugs to their
intended targets in an efficient and controlled
manner. Endovasc's lead drug candidates include
Angiogenix™ and Liprostin™. Endovasc also has a stent
coating technology, PROStent™, in pre-clinical trials.


For more information about Endovasc, please visit
http://www.endovasc.com.

Safe Harbor Statement

The foregoing statements are made under the "Safe
Harbor" Private Securities Litigation Reform Act of
1995 and may contain forward-looking statements that
involve risks and uncertainties that may not be
evident at the time of this release.



CONTACT: FOCUS Partners LLC
David Zazoff, 212-752-9445
[e-mail]